Pharmacokinetics of 8-hour intravenous infusion of NXY-059: A phase I, randomized, double-blind (within dose panels), placebo-controlled study in healthy Chinese volunteers

Clinical Therapeutics

Volumn 30, Issue 12, 2008, Pages 2342-2353

  Cheng, Yi Fang ^a   Jiang, Ji ^b   Hu, Pei ^b   Reinholdsson, Ingalill ^a   Guo, Wenyu ^c   Åsenblad, Nils ^a   Nilsson, Dag ^a  

^a ASTRAZENECA R AND D   (Sweden)

^b PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^c ASTRAZENECA   (United Kingdom)

Author keywords

acute ischemic stroke; Chinese volunteers; neuroprotection; NXY 059; pharmacokinetics; tolerability

Indexed keywords

DISUFENTON SODIUM; PLACEBO;

ADULT; AREA UNDER THE CURVE; ARTICLE; CAUCASIAN; CHINESE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG TOLERABILITY; ETHNIC DIFFERENCE; FEMALE; HUMAN; MALE; NEUROPROTECTION; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PLASMA CLEARANCE; POLYURIA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THIRST; URINARY TRACT INFECTION;

ADULT; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; BENZENESULFONATES; BODY MASS INDEX; CARDIOVASCULAR AGENTS; CHINA; CREATININE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; PLACEBOS; POLYURIA; SODIUM CHLORIDE; SOLUTIONS; TIME FACTORS;

EID: 58249140297     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2008.12.013     Document Type: Article

References (25)

1. Kuroda S., Tsuchidate R., Smith M.L., et al. Neuroprotective effects of a novel nitrone, NXY-059, after transient focal cerebral ischemia in the rat. J Cereb Blood Flow Metab. 19 (1999) 778-787
2. Sydserff S.G., Borelli A.R., Green A.R., and Cross A.J. Effect of NXY-059 on infarct volume after transient or permanent middle cerebral artery occlusion in the rat; studies on dose, plasma concentration and therapeutic time window. Br J Pharmacol. 135 (2002) 103-112
3. Marshall J.W., Cummings R.M., Bowes L.J., et al. Functional and histological evidence for the protective effect of NXY-059 in a primate model of stroke when given 4 hours after occlusion. Stroke. 34 (2003) 2228-2233
4. Wang C.X., and Shuaib A. NXY-059: A neuroprotective agent in acute stroke. Int J Clin Pract. 58 (2004) 964-969
5. Marshall J.W., Duffin K.J., Green A.R., and Ridley R.M. NXY-059, a free radical-trapping agent, substantially lessens the functional disability resulting from cerebral ischemia in a primate species. Stroke. 32 (2001) 190-198
6. Shuaib A., Lees K.R., Lyden P., et al., for the SAINT II Trial Investigators. NXY-059 for the treatment of acute ischemic stroke. N Engl J Med. 357 (2007) 562-571
7. Edenius C., Strid S., Borgå O., et al. Pharmacokinetics of NXY-059, a nitrone-based free radical trapping agent, in healthy young and elderly subjects. J Stroke Cerebrovasc Dis. 11 (2002) 34-42
8. Strid S., Borgå O., Edenius C., et al. Pharmacokinetics in renally impaired subjects of NXY-059, a nitrone-based, free-radical trapping agent developed for the treatment of acute stroke. Eur J Clin Pharmacol. 58 (2002) 409-415
9. Wemer J., Cheng Y.F., Nilsson D., et al. Safety, tolerability and pharmacokinetics of escalating doses of NXY-059 in healthy young and elderly subjects. Curr Med Res Opin. 22 (2006) 1813-1823
10. Lees K.R., Barer D., Ford G.A., et al., for the SA-NXY-0004 Investigators. Tolerability of NXY-059 at higher target concentrations in patients with acute stroke. Stroke. 34 (2003) 482-487
11. Pritchard J.B., and Miller D.S. Mechanisms mediating renal secretion of organic anions and cations. Physiol Rev. 73 (1993) 765-796
12. Ullrich K.J. Renal transporters for organic anions and organic cations. Structural requirements for substrates. J Membr Biol. 158 (1997) 95-107
13. Cheng Y.-F., Strid S., Borgå O., et al. Active renal secretion of NXY-059, a novel neuroprotectant, is mediated via an organic acid transporter. J Clin Pharmacol. 47 (2007) 909-914
14. Zhou H.H., Sheller J.R., Nu H., et al. Ethnic differences in response to morphine. Clin Pharmacol Ther. 54 (1993) 507-513
15. Cockcroft D.W., and Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron. 16 (1976) 31-41
16. Jaffé M. Uber den Niederschlag welchen Pikrinsäure in normalem Harn erzeugt und ueber eine neue Reaction des Kreatinins. Z Physiol Chem. 10 (1886) 391-400
17. Jönsson S., Cheng Y.F., Edenius C., et al. Population pharmacokinetic modelling and estimation of dosing strategy for NXY-059, a nitrone being developed for stroke. Clin Pharmacokinet. 44 (2005) 863-878
18. Gough K., Hutchison M., Keene O., et al. Assessment of dose proportionality: Report from the statisticians in the Pharmaceutical Industry/Pharmacokinetics UK Joint Working Party. Drug Inf J. 29 (1995) 1039-1048
19. Watabe M., Cheng Y.F., Nilsson D., et al. A phase 1, placebo-controlled, randomised, double-blind (within dose panels) study evaluating the safety, tolerability and pharmacokinetics of intravenous NXY-059 in Japanese subjects. Curr Med Res Opin. 23 (2007) 1849-1857
20. Lees K.R., Sharma A.K., Barer D., et al. Tolerability and pharmacokinetics of the nitrone NXY-059 in patients with acute stroke. Stroke. 32 (2001) 675-680
21. Kim K., Johnson J.A., and Derendorf H. Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms. J Clin Pharmacol. 44 (2004) 1083-1105
22. Hu O.Y., Ding P.Y., Huang C.S., et al. Pharmacokinetics of fosinoprilat in Chinese and whites after intravenous administration. J Clin Pharmacol. 37 (1997) 834-840
23. Leabman M.K., and Giacomini K.M. Estimating the contribution of genes and environment to variation in renal drug clearance. Pharmacogenetics. 13 (2003) 581-584
24. Lynch T., and Price A. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Physician. 76 (2007) 391-396
25. Poolsup N., Li Wan Po A., and Knight T.L. Pharmacogenetics and psychopharmacotherapy. J Clin Pharm Ther. 25 (2000) 197-220